EGFR and colorectal carcinoma: Although KRAS mutation is a predictive biomarker for the anti-EGFR therapy of CRC patients, whether it is an independent prognostic factor in CRC is controversial (Deng et al., 2015; Zocche et al., 2015; Kim et al., 2016; Charlton et al., 2017).